作者:Kittipan Siwawannapong、Ansley M. Nemeth、Roberta J. Melander、Jie Rong、Jonathan R. Davis、Masahiko Taniguchi、Morgan E. Carpenter、Jonathan S. Lindsey、Christian Melander
DOI:10.1002/cmdc.202200286
日期:2022.8.17
A boost for the approved: Multidrug-resistant bacteria are an increasing public health problem. One promising alternative to the development of new antibiotics is the use of antibiotic adjuvants, which would allow the continued use of FDA-approved antibiotics that have been rendered ineffective due to resistance. We identified a series of dipyrrins that supresses colistin resistance in highly resistant
批准的推动:多重耐药细菌是一个日益严重的公共卫生问题。开发新抗生素的一种有前途的替代方案是使用抗生素佐剂,这将允许继续使用 FDA 批准的因耐药性而失效的抗生素。我们鉴定了一系列双吡啉,可抑制肺炎克雷伯菌、鲍曼不动杆菌和铜绿假单胞菌的高耐药菌株中的粘菌素耐药性。在浓度为 15 μM 时,先导化合物可将粘菌素对肺炎克雷伯菌B9 的 MIC 值从 512 降低至 ≤1 μg/mL。